Ikena Oncology, Inc. (IKNA)

NASDAQ: IKNA · Real-Time Price · USD
1.700
+0.020 (1.19%)
Nov 20, 2024, 4:00 PM EST - Market closed
1.19%
Market Cap 82.04M
Revenue (ttm) 659,000
Net Income (ttm) -59.60M
Shares Out 48.26M
EPS (ttm) -1.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 15,786
Open 1.690
Previous Close 1.680
Day's Range 1.675 - 1.700
52-Week Range 1.220 - 2.320
Beta 0.49
Analysts Buy
Price Target 3.00 (+76.47%)
Earnings Date Nov 7, 2024

About IKNA

Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 26, 2021
Employees 43
Stock Exchange NASDAQ
Ticker Symbol IKNA
Full Company Profile

Financial Performance

In 2023, Ikena Oncology's revenue was $9.16 million, a decrease of -41.35% compared to the previous year's $15.62 million. Losses were -$68.17 million, -0.87% less than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for IKNA stock is "Buy." The 12-month stock price forecast is $3.0, which is an increase of 76.47% from the latest price.

Price Target
$3.0
(76.47% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Ikena Oncology Reports Third Quarter 2024 Financial Results

Strong financial position with $138 million in cash and investments at close of third quarter Strong financial position with $138 million in cash and investments at close of third quarter

13 days ago - GlobeNewsWire

Ikena Oncology Reports Second Quarter 2024 Financial Results

Strong financial position with $145 million in cash and investments at close of second quarter Strong financial position with $145 million in cash and investments at close of second quarter

3 months ago - GlobeNewsWire

UPDATE – Ikena Oncology Announces Strategic Update

Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Explorin...

6 months ago - GlobeNewsWire

Ikena Oncology Announces Strategic Update

Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Explorin...

6 months ago - GlobeNewsWire

Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update

Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and RAF m...

6 months ago - GlobeNewsWire

Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum

BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announ...

8 months ago - GlobeNewsWire

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in dos...

9 months ago - GlobeNewsWire

Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference

BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announc...

9 months ago - GlobeNewsWire

Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer

Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise

9 months ago - GlobeNewsWire

Ikena Oncology Outlines Key Priorities and Provides Corporate Updates

IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024 IK-595 first cohort treated and cleared safety evaluation window Focused execution on core ta...

10 months ago - GlobeNewsWire

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

Favorable safety profile in dose escalation shown to date; selective TEAD1 inhibition with IK-930 resulted in minimal treatment-related proteinuria without any dose reductions or treatment interruptio...

1 year ago - GlobeNewsWire

Ikena Oncology to Present at Multiple November 2023 Investor Conferences

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announc...

1 year ago - GlobeNewsWire

Ikena Oncology to Participate in September 2023 Investor Conferences

BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announ...

1 year ago - GlobeNewsWire

Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update

Initial clinical data for IK-930 monotherapy dose escalation expected in the fourth quarter 2023 IK-595, best-in-class MEK-RAF complex inhibitor, investigational new drug (IND) submission planned by y...

1 year ago - GlobeNewsWire

Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

Ikena receives approximately $43 million in net cash at closing New capital will further accelerate and expand development of Ikena's targeted oncology pipeline BOSTON and SOUTH SAN FRANCISCO, Calif.,...

1 year ago - GlobeNewsWire

Ikena Oncology to Participate in Upcoming Investor Conferences

BOSTON, May 24, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that mana...

1 year ago - GlobeNewsWire

Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline

Lead targeted oncology program in Hippo pathway, IK-930, continues to advance through dose escalation with no dose-limiting toxicities observed to-date

1 year ago - GlobeNewsWire

Ikena Oncology Announces $40 Million Underwritten Offering

BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, announced toda...

1 year ago - GlobeNewsWire

Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days

BOSTON, April 20, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that ma...

1 year ago - GlobeNewsWire

Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting

IK-930 is a potent Hippo pathway inhibitor that selectively binds TEAD1 and broadly represses oncogenic TEAD signaling IK-930's differentiated paralog selectivity and robust repressor activity in comp...

1 year ago - GlobeNewsWire

Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

Focused targeted oncology pipeline advancing towards multiple near-term milestones; runway into 2025

1 year ago - GlobeNewsWire

Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting

BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that th...

1 year ago - GlobeNewsWire

Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma

BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that th...

1 year ago - GlobeNewsWire

Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference

BOSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that man...

1 year ago - GlobeNewsWire

Ikena Oncology Appoints Owen Hughes as Board Chair

Owen Hughes joins Ikena Board as independent director with operational and public company experience

2 years ago - GlobeNewsWire